Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Kana Oiwa, MD, Naoko Hosono, MD, Rie Nishi, PhD, Takanori Ueda, MD PhD, Luigi Scott, PhD, Owen A. O'Connor, MD, PhD, Takahiro Yamauchi, MD PhD

Blood (2018) 132 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2018-99-110147

Published: 2018

Journal Articles

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Michael Svaton, MD, Karolina Skvarova Kramarzova, MSc, PhD, Veronika Kanderova, MSc, PhD, Petr Smisek, MD, Pavel Jesina, MSc, MD, PhD, Jakub Krijt, MSc, Blanka Stiburkova, MSc, PhD, Andrea Mancikova, MSc, Robert Dobrovolny, MSc, PhD, Violeta Bakardjieva-Mihaylova, MSc, Elena Vodickova, MD, Jan Stuchly, MSc, Tomas Kalina, MD PhD, Jan Stary, MD PhD, Jan Trka, MD PhD, Eva Fronkova, MD PhD, Viktor Kozich, MD PhD

Blood (2018) 132 (Supplement 1): 502.

https://doi.org/10.1182/blood-2018-99-113501

Published: 2018

Journal Articles

Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Yoshinobu Maeda, MD PhD, Kensei Tobinai, MD, PhD, Hirokazu Nagai, MD PhD, Takahiko Nakane, MD, PhD, Tatsu Shimoyama, MD, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, MD, PhD, Koji Izutsu, MD PhD, Ryuzo Ueda, MD PhD

Blood (2016) 128 (22): 4157.

https://doi.org/10.1182/blood.V128.22.4157.4157

Published: 2016

Journal Articles

Schedule-Dependent Synergy Between Belinostat and Pralatrexate in T-and B-Cell Lymphoma Cells in Vitro

Godefridus Peters, FHA van Gemert, I Kathmann, Saskia AGM Cillessen, MSc, G Jansen, Guru Reddy

Blood (2015) 126 (23): 5128.

https://doi.org/10.1182/blood.V126.23.5128.5128

Published: 2015

Journal Articles

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Kevin R. Kelly, MD PhD, Nashat Y. Gabrail, MD, William J Edenfield, MD, A Craig Lockhart, Anthony J. Olszanski, MDPhD, Guru Reddy

Blood (2015) 126 (23): 3966.

https://doi.org/10.1182/blood.V126.23.3966.3966

Published: 2015

Journal Articles

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Michael Mangone, PhD, Anna H Mei, BA, Luigi Scotto, PhD, Michele Visentin, PhD, Enrica Marchi, MD, PhD, I. David Goldman, MD, Constantine S. Mitsiades, MD, PhD, Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 4430.

https://doi.org/10.1182/blood.V122.21.4430.4430

Published: 2013

Journal Articles

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Matthew A Lunning, DO, Jason Gonsky, MD, PhD, Jia Ruan, MD, PhD, Adrienne A. Phillips, MD, MPH, Melissa Pulitzer, MD, Alison Moskowitz, MD, Christiane Querfeld, MD PhD, Patricia L Myskowski, M.D., Ariela Noy, MD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 2735.

https://doi.org/10.1182/blood.V120.21.2735.2735

Published: 2012

Journal Articles

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Michael Mangone, AB, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2011) 118 (21): 1831.

https://doi.org/10.1182/blood.V118.21.1831.1831

Published: 2011

Journal Articles

Effect of Genetic Polymorphisms Related to Folate and Homocysteine Metabolism In the Etiology of Recurrent Miscarriages

Elvira Maria Guerra-Shinohara, PhD, Kelma Cordeiro da Silva Giusti, Nathalia Sierra Monteiro, Robson José Lazaro, Fernanda Midori Seino, Carolina Tosin Bueno, Mário Henrique Burlacchini Carvalho, MD, PhD, Antônio Amorim Filho, MD, Carlos Chiattone, MD, PhD, Marcelo Zugaib, MD, PhD

Blood (2010) 116 (21): 5136.

https://doi.org/10.1182/blood.V116.21.5136.5136

Published: 2010

Journal Articles

The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number

Jannie Gregers, Ib Jarle Christensen, Kim Dalhoff, Birgitte Lausen, Henrik Schroeder, Steen Rosthoej, Niels Carlsen, Kjeld Schmiegelow, Curt Peterson

Blood (2010) 115 (23): 4671–4677.

https://doi.org/10.1182/blood-2010-01-256958

Published: 2010

Journal Articles

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

Steven M. Horwitz, MD, Julie M. Vose, M.D., Ranjana Advani, MD, Kamalesh Sankhala, MD, Swaminathan Padmanabhan, MD, Paul A. Hamlin, Jr., MD, Andy Chen, MD, PhD, Jasmine M Zain, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1674.

https://doi.org/10.1182/blood.V114.22.1674.1674

Published: 2009

Journal Articles

Altered Folate Metabolism Maybeo the Develop Linked tment of Acute Lymphoblastic Leukemia in African American Children.

Qing Chen, MD, Nancy Fassinger, RD, PhD, Ronald Thomas, PhD, Ana C. Xavier, MD, Yubin Ge, PhD, Larry H. Matherly, PhD, Jeffrey W. Taub, MD

Blood (2009) 114 (22): 4118.

https://doi.org/10.1182/blood.V114.22.4118.4118

Published: 2009

Journal Articles

Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia

Robert de Jonge, Wim J. E. Tissing, Jan Hendrik Hooijberg, Gerrit Jansen, Gertjan J. L. Kaspers, Jan Lindemans, Godefridus J. Peters, Rob Pieters

Blood (2009) 113 (10): 2284–2289.

https://doi.org/10.1182/blood-2008-07-165928

Published: 2009

Journal Articles

Pralatrexate (PDX) Compliments the Activity of the Proteasome Inhibitor Bortezomib (B) in in Vitro Models of Lymphoid T-Cell Malignancies

Enrica Marchi, MD, Luca Paoluzzi, MD, Seshan E Venkatraman, Owen A. O’Connor, MD, PhD

Blood (2008) 112 (11): 3619.

https://doi.org/10.1182/blood.V112.11.3619.3619

Published: 2008

Journal Articles

A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies.

Diane R. Mould, PhD, Kevin Sweeney, Stephen Duffull, Ellen Neylon, RN, Owen A. O’Connor, MD, PhD

Blood (2007) 110 (11): 1370.

https://doi.org/10.1182/blood.V110.11.1370.1370

Published: 2007

Journal Articles

Ancestry and pharmacogenetics of antileukemic drug toxicity

Shinji Kishi, Cheng Cheng, Deborah French, Deqing Pei, Soma Das, Edwin H. Cook, Nobuko Hijiya, Carmelo Rizzari, Gary L. Rosner, Tony Frudakis, Ching-Hon Pui, William E. Evans, Mary V. Relling

Blood (2007) 109 (10): 4151–4157.

https://doi.org/10.1182/blood-2006-10-054528

Published: 2007

Includes: Supplemental data

Journal Articles

Mutational Status in Genes of Folate Metabolism Is Associated with Toxicity of High-Dose Methotrexate in Patients with Immunocompetent Primary Central Nervous System Lymphoma.

Stefan Knop, MD, Markus Guenther, Juergen Loeffler, PhD, Agnieszka Korfel, MD, Michael Weller, MD, Hermann Einsele, MD, Holger Hebart, MD, Ulrich Herrlinger, MD

Blood (2006) 108 (11): 2580.

https://doi.org/10.1182/blood.V108.11.2580.2580

Published: 2006

Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD

Blood (2006) 108 (11): 1968.

https://doi.org/10.1182/blood.V108.11.1968.1968

Published: 2006

Journal Articles

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

Owen A. O’Connor, MD, PhD, P.A. Hamlin, MD, J. Gerecitano, MD, PhD, C.S Portlock, MD, A. Noy, MD, C. Moskowitz, MD, D.J. Straus, MD, D. Sarasohn, MD, O. Dumetrescu, MD, J. Pappanicolou, RN, E. Neylon, A.D. Zelenetz, MD, M.E. Saunders, MD, D.R. Mould, PhD, M. Fleischer, PhD, F. Sirotnak, PhD, S.M. Horwitz, MD

Blood (2006) 108 (11): 400.

https://doi.org/10.1182/blood.V108.11.400.400

Published: 2006

Journal Articles

Genetic Polymorphisms in the Folate Pathway and Risk of Childhood Acute Lymphoblastic Leukemia (ALL): MTHFR, MTHFD1, RFC1 and TS.

Allen Eng-Juh Yeoh, MD, Shirley Kow-Yin Kham, BSc, Yi Lu, PhD, Toon-Chai Foo, BSc, Hany Ariffin, MD, Thuan-Chong Quah, MD

Blood (2006) 108 (11): 2274.

https://doi.org/10.1182/blood.V108.11.2274.2274

Published: 2006

NARROW

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Schedule-Dependent Synergy Between Belinostat and Pralatrexate in T-and B-Cell Lymphoma Cells in Vitro

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Effect of Genetic Polymorphisms Related to Folate and Homocysteine Metabolism In the Etiology of Recurrent Miscarriages

The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

Altered Folate Metabolism Maybeo the Develop Linked tment of Acute Lymphoblastic Leukemia in African American Children.

Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia

Pralatrexate (PDX) Compliments the Activity of the Proteasome Inhibitor Bortezomib (B) in in Vitro Models of Lymphoid T-Cell Malignancies

A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies.

Ancestry and pharmacogenetics of antileukemic drug toxicity

Mutational Status in Genes of Folate Metabolism Is Associated with Toxicity of High-Dose Methotrexate in Patients with Immunocompetent Primary Central Nervous System Lymphoma.

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

Genetic Polymorphisms in the Folate Pathway and Risk of Childhood Acute Lymphoblastic Leukemia (ALL): MTHFR, MTHFD1, RFC1 and TS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only